Klow Blend (Peptide)

Klow Peptide is a multi-peptide research blend that combines four extensively studied compounds into a single lyophilized (also referred to as lyophilized) vial: BPC-157, TB-500, KPV, and GHK-Cu. Known interchangeably as Klow Blend and Klow Stack within the research community, this formulation is the only four-component peptide blend in the Healius Peptides catalog, bringing together tissue repair, cytoskeletal regulation, targeted anti-inflammatory action, and extracellular matrix remodeling (also spelled remodeling) into one research tool.^(1,2,3,4)

The Klow Peptide formulation builds on the established three-peptide foundation of BPC-157, TB-500, and GHK-Cu by adding KPV (Lysine-Proline-Valine), a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). While the first three components address vascularisation, cell migration, and structural matrix regeneration, KPV introduces a distinct anti-inflammatory and immunomodulatory layer that operates through NF-kB inhibition, suppression of pro-inflammatory cytokines, and support of the mucosal immune system. Preclinical evidence indicates that KPV retains the potent anti-inflammatory activity of its parent molecule, alpha-MSH, without the pigmentary side effects, making it a targeted addition to the blend’s investigational scope. ^(4,5)

Healius Peptides offers Klow Peptide in a single 80mg variant containing 10mg BPC-157, 10mg TB-500, 10mg KPV, and 50mg GHK-Cu. This balanced formulation provides equal doses of BPC-157, TB-500, and KPV alongside a GHK-Cu-dominant base, reflecting the peer-reviewed emphasis on copper peptide activity in regenerative and dermatological models. Every batch is manufactured under strict quality controls, 3rd-party tested, and verified to >99% purity, with full Certificates of Analysis available on the Healius Lab Testing.

Klow Peptide contains four active peptide components; each selected for its well-characterized (also referred to as characterized) role in regenerative and anti-inflammatory research. Understanding the individual profile of each ingredient is essential for researchers designing protocols around the Klow Stack formulation.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with a molecular weight of approximately 1,419 Da. Within the Klow Blend, BPC-157’s most critical contribution is its gastroprotective activity, which pairs directly with KPV’s PepT1-mediated intestinal targeting to create a dual-mechanism gastrointestinal research model. BPC-157 has demonstrated the ability to counteract NSAID-induced gastric damage, promote mucosal healing, and protect organ function by modulating the nitric oxide system and activating the FAK-paxillin pathway. Beyond the gut, BPC-157 also drives angiogenesis and upregulates growth factors in tendon, ligament, muscle, and bone repair models. ^(1,6)

TB-500 (Thymosin Beta-4 Fragment) is a 43-amino-acid peptide that governs actin polymerization and cytoskeletal organization (also referred to as organization). In the Klow Blend context, TB-500 serves as the cell-mobilization engine, preparing immune and repair cells for rapid migration to injury sites by reorganizing their internal actin scaffolding. This cytoskeletal priming is essential for the inflammatory and proliferative phases of wound healing. Preclinical data also show TB-500 suppressing pro-inflammatory cytokines, reducing oxidative stress markers, and promoting hair follicle stem cell activation, with favorable (also spelled favorable) outcomes across wound-healing, cardiac-repair, and fibrosis-reduction models. ^(2,7)

KPV (Lysine-Proline-Valine) is a tripeptide corresponding to residues 11 through 13 of alpha-melanocyte-stimulating hormone (alpha-MSH). Despite its small size of just three amino acids, KPV retains the potent anti-inflammatory activity of its parent molecule through mechanisms distinct from melanocortin receptor signaling (also spelled signaling). In vitro and in vivo studies demonstrate that KPV inhibits NF-kB activation by blocking the nuclear import of p65RelA, suppresses pro-inflammatory cytokines, including TNF-alpha and IL-6, and can be transported via the PepT1 di/tripeptide transporter in intestinal epithelial cells. This PepT1-mediated uptake mechanism is particularly significant because PepT1 expression is upregulated during inflammatory bowel conditions, making KPV a self-targeting anti-inflammatory agent in inflamed gut tissue. ^(4,5,8)

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper Complex) is a naturally occurring copper-binding tripeptide whose plasma concentrations decline from roughly 200 ng/mL at age 20 to 80 ng/mL by age 60. GHK-Cu’s defining research characteristic is its breadth of gene expression modulation: studies have documented it resetting over 4,000 human genes toward healthier expression patterns, spanning collagen and elastin synthesis, upregulation of antioxidant enzyme activity (superoxide dismutase, glutathione reductase), and suppression of inflammatory and tissue-destructive gene networks. Within the Klow Stack, GHK-Cu provides the structural matrix regeneration layer, rebuilding the extracellular scaffold that the other three components help protect and repopulate. ^(3,9)

Klow Peptide’s mechanism of action is best understood as a convergence of four complementary biological pathways. Each component activates distinct molecular targets, and the downstream effects overlap in ways that create a layered regenerative and anti-inflammatory research model.

The BPC-157 component primarily modulates the nitric oxide (NO) system and the FAK-paxillin pathway. In animal models, BPC-157 promotes endothelial cell proliferation and new blood vessel formation at injury sites, accelerating the delivery of nutrients and growth factors to damaged tissue. BPC-157 has also been shown to interact with the dopaminergic, serotonergic, and GABAergic systems, and to counteract the effects of several pharmacological agents on organ function in preclinical models. ^(1,6)

TB-500 contributes through its role as a key regulator of actin dynamics. By sequestering G-actin monomers and promoting their controlled polymerization into F-actin filaments, TB-500 facilitates the cytoskeletal reorganization required for cell migration into wound sites. This mechanism is critical for both the inflammatory and proliferative phases of tissue repair. In preclinical dermatological models, TB-500 has been shown to promote hair-follicle stem-cell migration, suppress pro-inflammatory cytokine production, and reduce oxidative stress markers. ^(2,7)

KPV provides the targeted anti-inflammatory layer that distinguishes Klow Peptide from other peptide blends. Unlike full-length alpha-MSH, which exerts anti-inflammatory effects via melanocortin receptor (MCR) activation, KPV operates through a non-receptor-mediated mechanism. Mechanistic studies show that KPV translocates directly into the cell nucleus, where it stabilizes IkB-alpha and competitively blocks the interaction between importin-alpha-3 and the p65RelA subunit of NF-kB, thereby preventing nuclear translocation of NF-kB and subsequent transcription of inflammatory genes. ^(4,5,8) In intestinal epithelial cells, KPV is actively transported via the PepT1 transporter, which is upregulated during inflammatory bowel conditions, creating a targeted delivery mechanism to the tissues where anti-inflammatory action is most needed. ⁽⁵⁾

GHK-Cu provides the matrix-level regenerative component. As a copper-delivery peptide, GHK-Cu activates metalloproteinases involved in extracellular matrix turnover while simultaneously stimulating the synthesis of new collagen types I, III, and V, as well as elastin, decorin, and glycosaminoglycans. GHK-Cu has been shown to upregulate genes associated with antioxidant defense (superoxide dismutase, glutathione reductase) and to downregulate genes linked to inflammation and tissue destruction. ^(3,9)

When combined in the Klow Peptide formulation, these four mechanisms create a layered research model: BPC-157 drives vascularisation and systemic repair signaling, TB-500 enables cellular migration and cytoskeletal readiness, KPV suppresses inflammatory cascades at the transcriptional level, and GHK-Cu rebuilds the structural matrix and resets gene expression toward regenerative activity. No other blend in the Healius catalog covers four distinct biological pathways in a single vial.

The research benefits of Klow Peptide stem from the combined investigational profiles of its four components. Hundreds of peer-reviewed studies across the BPC-157, TB-500, KPV, and GHK-Cu literature support the following areas of interest for the Klow Blend formulation.

In tissue repair and wound healing research, BPC-157 has demonstrated accelerated recovery in preclinical models involving tendons, ligaments, muscles, and bone fractures. ⁽¹⁾ TB-500 has shown the ability to promote cell migration into wound sites and improve functional recovery outcomes. ⁽²⁾ GHK-Cu stimulates collagen and elastin synthesis and activates dermal fibroblasts at injury sites. ⁽³⁾ KPV adds a distinct healing dimension by reducing inflammatory cytokine levels at the wound site, which can prevent the chronic inflammation that delays tissue repair in many preclinical models. ⁽⁴⁾

In gastrointestinal research, KPV is the standout component. Murine colitis models (both DSS-induced and TNBS-induced) have shown that KPV, delivered orally, significantly reduced clinical and histological signs of intestinal inflammation. ⁽⁵⁾ The PepT1-mediated uptake mechanism ensures that KPV is concentrated in the inflamed intestinal epithelium, where its anti-inflammatory action is most relevant. Combined with BPC-157’s established gastroprotective properties, including its ability to counteract NSAID-induced gastric damage and promote mucosal healing, the Klow Blend offers researchers a dual-mechanism approach to gastrointestinal inflammation models. ^(1,5,6)

In skin and dermatological research, GHK-Cu stands as the primary matrix-regenerative component. Ex vivo and preclinical skin models report increased skin thickness, improved elasticity, reduced fine lines, and enhanced color (also spelled color) uniformity following GHK-Cu treatment. ⁽⁹⁾ KPV contributes through its documented effects on skin inflammation, including reduced inflammatory cytokine and chemokine levels in skin tissues, limited immune cell migration to sites of skin injury, and accelerated wound closure in dermatitis models. ⁽⁴⁾ BPC-157 supports dermal blood supply through angiogenesis, while TB-500 promotes hair follicle stem cell activation. ^(2,7)

In anti-inflammatory and immunomodulatory research, Klow Peptide provides four converging anti-inflammatory pathways. KPV inhibits NF-kB nuclear translocation and suppresses TNF-alpha and IL-6 production. ^(4,5) BPC-157 modulates systemic inflammatory cytokine cascades. ⁽¹⁾ TB-500 suppresses NF-kB-mediated inflammation and reduces oxidative stress markers. ⁽²⁾ GHK-Cu downregulates genes associated with chronic inflammation. ⁽³⁾ This multi-pathway coverage makes Klow Peptide particularly suited to research protocols investigating complex inflammatory conditions where single-target interventions may be insufficient.

In anti-aging (also spelled aging) and longevity research, GHK-Cu’s ability to reset over 4,000 human genes toward youthful expression patterns is complemented by KPV’s suppression of chronic low-grade inflammation, a hallmark of biological aging sometimes referred to as “inflammaging” in the gerontological literature. Combined with BPC-157’s systemic protective effects and TB-500’s regenerative cell-migration properties, the Klow Blend provides researchers with a four-axis model for studying age-related tissue decline and inflammation-driven degeneration.

Klow Peptide dosage in research settings varies depending on the experimental model, target tissue, and specific outcomes under investigation. The peer-reviewed literature on each component provides dosing frameworks that inform the design of the Klow Blend protocol.

BPC-157 has been studied at doses ranging from 1 to 10 mcg/kg in preclinical models, administered via subcutaneous, intraperitoneal, or intragastric routes depending on the target tissue. ⁽¹⁾ TB-500 research protocols typically utilize doses in the range of 2 to 6 mg per administration in larger animal models, with frequency varying from daily to twice weekly. ⁽²⁾ GHK-Cu has been investigated at concentrations ranging from 0.1 to 10 mcg/mL in cell culture systems, and at systemic doses from 0.5 to 5 mg/kg in animal models. ⁽³⁾ KPV has been studied at various concentrations in cell culture (10 nmol/L to 100 micromol/L) and has shown anti-inflammatory efficacy in murine colitis models when delivered orally, suggesting broad dose-response flexibility. ⁽⁵⁾

The Healius Klow Peptide Dosage Calculator provides a tool for researchers to calculate reconstitution volumes and individual component concentrations per injection volume for the 80mg vial.

Multi-peptide blend protocols in the literature generally follow a loading phase of higher-frequency administration (typically daily for 4 to 6 weeks), followed by a maintenance phase at reduced frequency (2 to 3 times per week). Optimal dosing for the combined Klow Stack formulation has not been established in human clinical trials, and all dosage information is extrapolated from preclinical data for the individual components. Independent ethical review and institutional oversight are essential before initiating any in vivo research protocol.

1. Seiwerth S, et al. “BPC 157’s effect on healing.” Journal of Physiology-Paris, 1999; 93(6): 441-456. Comprehensive review of BPC-157 mechanisms, including gastric pentadecapeptide activity, nitric oxide modulation, angiogenesis promotion, and tissue repair across tendon, ligament, muscle, and bone preclinical models.

2. Goldstein AL, et al. “Thymosin beta-4: a multi-functional regenerative peptide.” Expert Opinion on Biological Therapy, 2012; 12(Suppl 1): S37-S51. Review of TB-500/Thymosin Beta-4 mechanisms, including actin regulation, cell migration, wound healing, hair follicle stem cell activation, and anti-inflammatory properties.

3. Pickart L, et al. “The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging.” International Journal of Molecular Sciences, 2012; 13(9): 11699-11720. Key study on GHK-Cu gene expression modulation (4,000+ genes), collagen synthesis stimulation, antioxidant enzyme upregulation, and age-related decline in plasma GHK-Cu concentrations.

4. Luger TA et al. “Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.” Annals of the New York Academy of Sciences, 2003; 994: 133-140. Review establishing that the C-terminal tripeptide KPV retains the potent anti-inflammatory activity of full-length alpha-MSH through NF-kB inhibition and cytokine modulation, without melanocortin receptor-dependent pigmentation effects.

5. Dalmasso G et al. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology, 2008; 134(1): 166-178. Landmark study demonstrating KPV anti-inflammatory activity via PepT1-mediated transport in intestinal epithelial cells, NF-kB inhibition independent of melanocortin receptors, and significant reduction of DSS- and TNBS-induced colitis in murine models.

6. Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Current Pharmaceutical Design, 2011; 17(16): 1612-1632. Detailed examination of BPC-157 gastroprotective effects, cytoprotective mechanisms, interaction with the NO system, and FAK-paxillin pathway modulation in multiple organ damage models.

7. Sosne G et al. “Thymosin beta 4 promotes dermal healing.” Annals of the New York Academy of Sciences, 2010; 1194: 112-117. Study demonstrating TB-500 activity in dermal wound-healing models, including promotion of cell migration, anti-inflammatory effects, and modulation of the NF-kB pathway.

8. Brzoska T, et al. “Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.” Journal of Leukocyte Biology, 2012; 92(3): 547-556. Mechanistic study demonstrating KPV nuclear import, competitive blockade of importin-alpha-3/p65RelA interaction, IkB-alpha stabilization, and suppression of chemokine signaling in airway epithelium.

9. Pickart L, Margolina A. “Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data.” International Journal of Molecular Sciences, 2018; 19(7): 1987. Updated analysis of GHK-Cu gene expression data showing upregulation of collagen, elastin, decorin, and glycosaminoglycan synthesis genes, plus downregulation of inflammatory and tissue-destructive gene networks.

10. Vasireddi N, et al. “Emerging Use of BPC-157 in Orthopedic Sports Medicine: A Systematic Review.” HSS Journal, 2025. Systematic review covering BPC-157 mechanism of action, musculoskeletal effects, metabolism, safety profile, and regulatory/WADA status across published preclinical literature.

11. Kannengiesser K et al. “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflammatory Bowel Diseases, 2008; 14(3): 324-331. Preclinical evidence for KPV anti-inflammatory activity in IBD models, including NF-kB modulation, TNF-alpha suppression, and mucosal immune support.

This product is intended for research use only (RUO). It is not intended for human or veterinary diagnostic, therapeutic, or clinical use. Klow Peptide is not a drug, food, cosmetic, or dietary supplement and may not be misbranded, misused, or mislabeled as such. All information provided in this product description is for educational and informational purposes only and is based on published peer-reviewed research. Healius Peptides makes no claims regarding the therapeutic efficacy of this product in humans. Researchers are responsible for ensuring compliance with all applicable local, state, federal, and international regulations governing the purchase, handling, and use of research peptides.